A new real-world study in Greece finds that for high-risk patients, COVID-19 antivirals are highly effective in reducing the risk of both hospitalization and death. The study is published in The Journal of Infectious Diseases.
Patients who were older than 75, and reported good drug adherence benefitted the most from the drugs molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid)
Older adults who are hospitalized for COVID-19 have double the rate of death upon discharge as older adults hospitalized for influenza-related complications, according to a new study in The BMJ.
A descendant of Omicron, Eris, or EG.5.1, was first classified as a variant in the UK on 31 July, but now accounts for one in 10 Covid cases.
It is now the second most prevalent variant in the UK, after Arcturus which makes up almost half of all infection cases at 39.4 per cent, according to UKHSA.
